T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Conditions
- Refractory Solid Cancer Patients Unexposed to Immunotherapy
Interventions
- DRUG: Tisleizumab(BGB-A317)
Sponsor
Samsung Medical Center